| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $3,016,022 ) |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG065154 | Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial | 000 | 5 | NIH | 11/15/2024 | $2,139,870 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI181542 | The Role of the EphA2 Receptor Kinase Pathway in Pneumocystis Pneumonia (PCP) | 000 | 2 | NIH | 10/31/2024 | $195,698 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA278908 | Overcoming tumor-intrinsic mechanisms of immune evasion to boost systemic response to radiotherapy | 000 | 1 | NIH | 10/16/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R33NS114147 | Development of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation | 000 | 2 | NIH | 10/16/2024 | $119,654 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R35GM136262 | Structural biology of DNA damage response in chromatin | 000 | 5 | NIH | 11/8/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K12AR084222 | Mayo Clinic Building Interdisciplinary Research Careers in Women’s Health | 000 | 16 | NIH | 11/6/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K12AR084222 | Mayo Clinic Building Interdisciplinary Research Careers in Women’s Health | 000 | 16 | NIH | 11/6/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R35GM143949 | Fundamental and applied studies of nucleic acids | 000 | 3 | NIH | 11/7/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DE029832 | Genetic, Tissue, and Anatomical Interactions in Mandibulofacial Dysmorphogenesis | 002 | 4 | NIH | 11/7/2024 | $1,004,166 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01HL152967 | Therapeutic ECM Resorption in Cellular Systems and Precision Cut Lung Slices. | 000 | 4 | NIH | 11/14/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UG1CA232760 | NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 | 000 | 6 | NIH | 10/17/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB030529 | FHIRCat: Enabling the Semantics of FHIR and Terminologies for Clinical and Translational Research | 000 | 4 | NIH | 10/18/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K99NS126417 | Microglial P2Y6 receptor calcium signaling as a core regulator of epileptogenesis | 000 | 2 | NIH | 10/15/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3AG067593 | Non-pharmacological Options in postoperative Hospital-based And Rehabilitation pain Management (NOHARM) pragmatic clinical trial | 000 | 5 | NIH | 11/15/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01DK115575 | Fecal Incontinence Treatment Study (FIT Study) | 000 | 5 | NIH | 11/14/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA235026 | Integration of germline and tumor genomes in CLL | 000 | 5 | NIH | 10/18/2024 | -$48,092 |
| | 2025 | 2023 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23NS112339 | Localizing value and underlying mechanisms of low frequency EEG for focal epilepsy | 000 | 5 | NIH | 10/15/2024 | -$13,820 |
| | 2025 | 2023 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R00CA252044 | Therapeutic potential of FANCM for BRCA1-linked cancer | 000 | 3 | NIH | 10/10/2024 | $84,134 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AA027179 | Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer | 000 | 5 | NIH | 10/10/2024 | -$30,009 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R33AG058738 | Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology Project | 000 | 5 | NIH | 10/11/2024 | $0 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS112176 | Development of advanced voltammetric method for basal neurotransmitter level measurement | 000 | 4 | NIH | 10/15/2024 | $0 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U54AG044170 | Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease | 000 | 10 | NIH | 10/30/2024 | -$1,758 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U54AG044170 | Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease | 000 | 10 | NIH | 10/30/2024 | -$55,913 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03CA241020 | 3D Ultra-sensitive Ultrasound Microvessel Imaging for Breast Mass Differentiation | 000 | 2 | NIH | 11/5/2024 | -$2,540 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01AA021788 | Liquid biopsy for alcoholic hepatitis: diagnosis, prognosis and technology development | 000 | 10 | NIH | 11/1/2024 | -$1 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3AA026887 | Assessment of Alcoholic Hepatitis with Multiparametric Magnetic Resonance Elastography | 000 | 5 | NIH | 11/4/2024 | -$75,038 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI159230 | Lethal human brain infection by measles virus: phylogeography and mechanisms | 000 | 2 | NIH | 10/30/2024 | $0 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA096985 | BubRI in Cancer and Aging | 000 | 20 | NIH | 11/5/2024 | -$153,040 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR055563 | Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes | 000 | 10 | NIH | 11/4/2024 | -$10,418 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK113999 | Stories for Change (S4C): Digital Storytelling for Diabetes Self-Management among Hispanic Adults | 000 | 4 | NIH | 10/16/2024 | -$12,811 |
| | 2025 | 2022 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG060637 | Novel Signaling Pathways Underlying Skeletal Muscle Atrophy | 000 | 5 | NIH | 10/11/2024 | $0 |
| | 2025 | 2021 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R61NS114147 | Deve inlopment of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation | 000 | 1 | NIH | 10/16/2024 | -$119,654 |
| | 2025 | 2021 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | 90DPTB0012 | Mayo Clinic Traumatic Brain Injury Model System | 03 | 5 | ACL | 10/10/2024 | -$344 |
| | 2025 | 2021 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UH3NS095495 | Neurophysiologically Based Brain State Tracking & Modulation in Focal Epilepsy | 000 | 5 | NIH | 11/14/2024 | -$1 |
| | 2025 | 2021 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI129191 | Memory T Cell Development and Survival in T Cell Responses of Older Individuals | 000 | 6 | NIH | 10/29/2024 | $0 |
| | 2025 | 2020 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | 90DPTB0012 | Mayo Clinic Traumatic Brain Injury Model System | 03 | 5 | ACL | 10/10/2024 | $0 |
| | 2025 | 2020 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA251923 | Blood-based biomarker of therapeutic efficacy for mesothelioma | 000 | 1 | NIH | 10/29/2024 | -$4,061 |
|
| Issue Date FY: 2024 ( Subtotal = $277,738,714 ) (Continued on the next page) |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS112153 | Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s disease | 001 | 2 | NIH | 7/11/2024 | $40,350 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG087387 | Investigating the Role of Adipose Senescent Cells in Cognitive Function and Alzheimer's Disease Progression | 000 | 1 | NIH | 8/8/2024 | $508,525 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD017217 | Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health. | 000 | 3 | NIH | 6/21/2024 | $163,620 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160761 | Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology | 001 | 3 | NIH | 6/24/2024 | $50,844 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U24CA258058 | BRCA1/2 and Hereditary Breast, Ovarian and Pancreatic (HBOP) Cancer Variant Curation Expert Panels | 000 | 3 | NIH | 8/22/2024 | $83,063 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL151379 | Evaluating the natural evolution of myocardial stiffness in aging, sex differences, and through menopause transition in women, using a free-breathing magnetic resonance elastography approach | 001 | 2 | NIH | 6/12/2024 | $46,728 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK114007 | Mechanisms of alteration of gastrointestinal physiology by gut microbes | 000 | 8 | NIH | 6/26/2024 | $559,098 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HS028639 | SDMo – a measure of the occurrence of SDM in the care of patients with chronic conditions | 000 | 3 | AHRQ | 9/18/2024 | $498,849 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA210138 | Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer | 001 | 8 | NIH | 8/6/2024 | $660,703 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137800 | Efficacy and Safety of Proteolytic Activity-Guided fecal Microbiota Transplantation for Irritable Bowel Syndrome (PRAGMAT trial) | 000 | 1 | NIH | 8/26/2024 | $316,102 |
| | 2024 | 2024 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160761 | Mechanisms of Clinical and Hemodynamic Response to Pulmonary Vasodilator Therapy in Fontan physiology | 000 | 3 | NIH | 11/28/2023 | $571,997 |
|
